Labskin STOER study demonstrates 54% increase in skin hydration in 24 hours
Promotion of new skin cells leaving fresher looking skin
Launch of New Animal-Free Labskin Dandruff Test
Integumen today announces the completion of development and launch of a new dandruff test on its animal-free Labskin test platform. The Company also reports additional successful results of research assessing the impact of STOER products on rehydration of the skin.
Unique Animal-Free Anti-Dandruff testing:
The new Labskin test uses a unique scalp variation that mimics skin bacteria and dandruff, in both healthy and ‘itchy’ states. This allows for dandruff relief and scalp protection products to be tested effectively on a realistic human skin model in a laboratory setting without the need to test on animals.
Labskin full thickness human skin equivalent is suitable for testing irritation under guideline 439 of the OECD* (see below). Populating and growing bacteria, sourced from human scalp, onto Labskin, clearly demonstrates the effective response of the irritation and hydration tests.
STOER For Men Serum Labskin tests improves skin hydration
Labskin treated with STOER Serum demonstrated a 54% increase in skin hydration after 24 hours and 22% higher after 48 hours. This effect was seen in the lower layers of the epidermis and at the junction with the dermis, not just the surface. The depth of hydration seen in results of this study validate the long-term effects of using the STOER Serum.
STOER Power Mask Labskin test packs a punch
The hydration of Labskin treated with STOER Power Mask was 63% higher after 24 hours and 34% higher after 48 hours. As with the STOER Serum, this effect was seen in the lower layers of the epidermis and at the junction with the dermis, not just the surface, demonstrating a long-lasting effect on the skin.
Gerard Brandon (CEO of Integumen plc) commented:
“Integumen’s strategy is to provide a unique animal-free skin testing platform to test and validate product effects in the pharma, healthcare and beauty industries. Since the beginning of the year, Labskin has demonstrated the ability to substantiate accurate skin care product claims beyond the usual 74% of women or men. We work with our skin care partners who are constantly looking for that competitive edge, to prove the impact of their product claims while maintaining an ethical product on the market.
“Our new Labskin dandruff scalp test not only provides a human skin model in a laboratory setting without the need to test on animals but opens the door to the global hair care market which is expected to reach USD $110.70 Billion by 2024*.”
Laboratory grown human skin testing services. Specifically developed to host harmful bacteria on simulated human skin. It is the best testing platform for antimicrobial products, such as anti-dandruff shampoos and anti-acne creams, anti-aging, anti-fungal, UV sun exposure, toxic shock, and drug delivery through the skin, which cannot currently be carried out in vivo (animal models) due to ethical constraints of testing harmful bacteria.
* OECD Guidelines for the Testing of Chemicals are a set of internationally accepted specifications for the testing of chemicals decided on by the Organisation for Economic Co-operation and Development. They were first published in 1981.
** Source: https://www.globenewswire.com/news-release/2018/07/09/1534543/0/en/Global-Hair-Care-Market-Expected-to-Reach-USD-110-70-Billion-by-2024-Zion-Market-Research.html
Big data analytics is key to transforming the future of skin disease drug development which is ranked as the fourth most common cause of human illness. While drug companies still chase molecules for new blockbuster drugs, millions of people are suffering from skin related diseases today.
Revenues grew by 890% to £477,000 (unaudited), combined with revenues for RinoCloud, prior to their acquisition, Group revenues jumped 1,213% to £655,000
Integumen Annual Report at 31 December 2018
Integumen signs 3 contracts and continues to make rapid progress up the value chain by entering into larger contracts for Labskin AI services.
FY 2018 total revenue £502k increased 111% (FY 2017 : £238k);
FY 2018 revenue from continued operations £274k increased 294% (FY 2017 : £93k) following Labskin test kit sales move to full skin-care product test services;
FY 2018 EBITDA losses reduced by 12% to (£1.25m) (FY 2017: (£1.40m))
Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials. Combined with human volunteers doubles number of skin tests possible saving time and money.